On the advice from the independent data safety monitoring board, a Democratic Republic of Congo-based clinical trial, PALM, evaluating Regeneron Pharmaceuticals’ (REGN -1%) REGN-EB3, NIH’s mAb114, Gilead Sciences’ (GILD -1.2%) GS-5734 (remdesivir) and Mapp Biopharmaceuticals’ ZMapp (control) in people infected with the Ebola virus has been stopped early after preliminary mortality data showed REGN-EB3’s superiority to ZMapp in preventing deaths.
Orphan Drug-tagged REGN-EB3 is a cocktail of three fully-human monoclonal antibodies based on the company’s VelociSuite platform.
ZMapp is a cocktail of three humanized monoclonal antibodies while mAb114 is a single monoclonal antibody. Remdesivir is a nucleotide prodrug that blocks a key enzyme that the virus needs for replication.
Development of REGN-EB3 is ongoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.